Sharps Compliance acquired by Aurora Capital Partners: fairness opinion by Raymond James
Deal terms
Implied value per share by method vs. $8.75 offer
Ranges as disclosed in the banker’s summary of analyses; the red line marks the per-share consideration.
Opinion of Raymond James to the target board
Discounted cash flow assumptions
Present value divided by fully diluted Shares outstanding as of June 30, 2022. Mean EV/TTM EBITDA of precedents 14.0x; mean EV/NTM EBITDA 11.3x; mean EV/TTM Revenue 2.6x; mean EV/NTM Revenue 2.4x.
Selected public companies (4)
Stericycle, Inc. · Clean Harbors, Inc. · Harsco Corporation · Heritage-Crystal Clean, Inc.
| Multiple | Peer low | Peer median | Peer high | Range applied | Implied per share |
|---|---|---|---|---|---|
| EV / LTM March-2022 EBITDA | — | — | — | 6.3x–13.6x | $2.23–$3.61 |
| EV / 2023E EBITDA | — | — | — | 6.6x–11.8x | $3.39–$5.14 |
| EV / LTM March-2022 Revenue | — | — | — | 1.1x–2.3x | $4.84–$8.41 |
| EV / 2023E Revenue | — | — | — | 1.0x–2.2x | $4.91–$9.02 |
Selected precedent transactions (8)
| Date | Target | Acquirer | Multiple |
|---|---|---|---|
| 2022-05 | US Ecology, Inc. | Republic Services, Inc. | — |
| 2022-01 | ITRenew, Inc. | Iron Mountain Incorporated | — |
| 2021-11 | Covanta Holding Corporation | EQT Partners AB | — |
| 2020-10 | Advanced Disposal Services, Inc. | Waste Management, Inc. | — |
| 2019-11 | NRC Group Holding Corp. | US Ecology, Inc. | — |
| 2017-03 | G&K Services, Inc. | Cintas Corporation | — |
| 2016-05 | Recall Holdings Limited | Iron Mountain Incorporated | — |
| 2015-10 | Shred-it Internal Inc | Stericycle, Inc | — |
| Multiple | Low | Median | High | Range applied | Implied per share |
|---|---|---|---|---|---|
| EV / TTM EBITDA | 11.9x | 13.7x | 16.6x | 11.9x–16.6x | $3.19–$4.00 |
| EV / NTM EBITDA | 8.5x | 11.8x | 13.0x | 8.5x–13.0x | $4.02–$5.55 |
| EV / TTM Revenue | 2.2x | 2.5x | 3.3x | 2.2x–3.3x | $8.60–$12.36 |
| EV / NTM Revenue | 2.0x | 2.4x | 3.1x | 2.0x–3.1x | $8.52–$12.25 |
Other analyses
| Analysis | Summary | Implied per share |
|---|---|---|
| Historical Trading Range (informational only) | For the period ending July 8, 2022: one day prior share price $2.92; one week prior $2.88; one month prior $3.82; 52-week trading high $10.47; 52-week VWAP $6.74; closing price of $3.01 on July 8, 2022, compared to the $8.75 offer price. Presented for reference only and not relied upon for valuation purposes. | $2.88–$10.47 |
Opinion fee of $500,000 paid upon delivery of the opinion. Advisory fee equal to the greater of $1,500,000 or 1.50% of sale transaction value, contingent upon closing; $25,000 retainer offset against the advisory fee. Expense reimbursement capped at $50,000. During prior two years Raymond James received $275,000 from the Company ($25,000 retainer and $250,000 buy-side fees).
Management projections
| Projection year | Year 1 | Year 2 | Year 3 | Year 4 | CAGR |
|---|---|---|---|---|---|
| Revenue | $80.5M | $88.4M | $98.3M | $104M | 8.9% |
| Revenue growth | 9.7% | 9.8% | 11.2% | 5.8% | |
| EBITDA | $9.7M | $12.8M | $17.5M | $19.5M | 26.2% |
| EBITDA growth | 41.0% | 32.0% | 36.7% | 11.4% | |
| EBITDA margin | 12% | 14% | 18% | 19% | |
| Implied EV / EBITDA | 17.9x | 13.5x | 9.9x | 8.9x |
Year-1 growth is against LTM at announcement ($73.4M revenue, $6.9M EBITDA); later years are year over year.
Raymond James used Management Forecasts prepared by Sharps management covering calendar years 2023 through 2027, together with extrapolations of those forecasts prepared by Raymond James with the Company's consent, in its discounted cash flow analysis. The forecasts also supplied LTM March-2022 and 2023E Adjusted EBITDA and Revenue used in the public trading multiples and selected transactions analyses. Specific revenue and EBITDA dollar figures were not included in the sliced sections.
Process notes
Other Outsourced Services fairness opinions
- CynergisTek / Clearwater Compliance 2022
- R1 RCM / TowerBrook and CD&R 2024 · 13.6x EV/EBITDA
- Stericycle / Waste Management 2024 · 15.1x EV/EBITDA
- BioTelemetry / Philips 2020 · 23.7x EV/EBITDA
- Cross Country Healthcare / Aya Healthcare 2024 · 12.1x EV/EBITDA
- Premier / Patient Square Capital 2025 · 10.9x EV/EBITDA